Improved Fetal Hemoglobin With mTOR Inhibitor–Based Immunosuppression in a Kidney Transplant Recipient With Sickle Cell Disease. Issue 8 (30th March 2017)

• Record Type: Journal Article
• Authors: Gaudre, N.; Cougoul, P.; Bartolucci, P.; Dörr, G.; Bura‐Riviere, A.; Kamar, N.; Del Bello, A.
• Is Part Of: American journal of transplantation. Volume 17:Issue 8(2017)
• Page Start: 2212
• Page End: 2214
• Publication Date: 2017-03-30
• Subjects: clinical research/practice -- kidney transplantation/nephrology -- anemia -- immunosuppressant -- mechanistic target of rapamycin -- everolimus -- kidney disease; Transplantation of organs, tissues, etc -- Periodicals; 617.95
• DOI: 10.1111/ajt.14263
• Languages: English
• ISSNs: 1600-6135

Abstract

Abstract : Fetal hemoglobin induction is a key point in the management of sickle cell disease (SCD). We report the case of a kidney transplant recipient with SCD who was treated with everolimus, a mammalian target of rapamycin inhibitor. At 10 months after initiating therapy, the patient's fetal hemoglobin level was dramatically increased (from 4.8% to 15%) and there was excellent tolerance to treatment. Abstract : A kidney transplant recipient with sickle cell disease experiences a major increase in fetal hemoglobin after the introduction of a mammalian target of rapamycin inhibitor.